How to Check ClinicalTrials.gov and FDA Status for a Research Compound

“Is it in a clinical trial?” and “Is it FDA approved?” are separate questions. ClinicalTrials.gov is a registry and results database maintained by the National Library of Medicine. FDA approval is a regulatory action tied to a defined finished product, application, labeling, and intended use.

A compound can appear in registered research without being approved. A substance can have an FDA Unique Ingredient Identifier without being approved. A product can have a National Drug Code without being approved. The reliable workflow is to check each official system for the narrow fact it is designed to provide.

Part 1: Check ClinicalTrials.gov

1. Build an alias list

Start with the exact compound name, then add documented synonyms, development codes, generic or nonproprietary names, and common spelling variants. Search each separately. Do not assume that two similar names describe the same molecule.

Record the search terms and date. Trial records change, and older records may use a code name that later changed.

2. Separate study types

Open each plausible record and identify whether it is interventional, observational, or expanded access. An observational record does not mean researchers assigned the compound. An interventional record does not, by itself, show a favorable result.

ClinicalTrials.gov’s official reading guide identifies the NCT number, sponsor, responsible party, overall status, posted dates, study details, results, and record history as distinct parts of a record.[1]

3. Read status and dates literally

Recruiting, active but not recruiting, completed, terminated, withdrawn, and unknown describe study status, not whether the intervention succeeded. Recruiting means participants are currently being recruited, whether or not anyone has yet enrolled. Completed means the study concluded normally and the last participant’s last visit occurred; it does not mean an endpoint was met or that results were posted. “Unknown” is assigned when the last known status was recruiting, not yet recruiting, or active not recruiting, the completion date has passed, and the record has not been verified within two years; it is not a current sponsor confirmation. Also check:

• the record verification date;
• the study start and completion dates;
• whether enrollment is estimated or actual;
• when the record was first posted and last updated;
• the history of changes.

ClinicalTrials.gov defines the record verification date as the date on which the responsible party last confirmed the record’s information, and defines recruitment statuses separately.[2][3] A stale record deserves cautious wording.

4. Verify the intervention and question

Read the intervention names, descriptions, arms, eligibility criteria, sponsor, primary outcomes, outcome time frames, and study design. Confirm that the record actually concerns the compound and question of interest rather than a similarly named material or a different use.

The primary outcome measures are the outcome measure or measures of greatest importance specified in the protocol and are usually used in power planning; a study may have more than one. Record every primary outcome and time frame, and check the time-stamped record history, protocol, or statistical analysis plan before calling an outcome prespecified.[3]

5. Check for posted results and publications

The Results tab, when present, may include participant flow, baseline characteristics, outcome tables, statistical analyses, and adverse-event information. “Results submitted” is not the same as “results posted.” The official results guide explains the difference and shows where outcome type and time frame appear.[4][5]

Posted summary results remain sponsor- or investigator-submitted. ClinicalTrials.gov staff review them for apparent errors and clarity, not scientific accuracy; posting is not U.S. government validation of the analysis or conclusions.[6][15]

Search the NCT number in PubMed and on the web to find linked publications. Then compare the registry and paper:

• Do the primary outcomes and time frames match?
• Are all registered arms and outcomes reported?
• Did enrollment or eligibility change?
• Are analyses labeled prespecified or post hoc?
• Does the publication describe the same material?

Trial registration and a publication are complementary records. They can disagree, so compare the time-stamped record, protocol or statistical analysis plan, and paper rather than treating one as automatic verification of another. Keep cell, animal, and human evidence separate when the linked publications span different models.

6. Preserve the narrow conclusion

Use language such as:

• “A study was registered with status listed as completed; no summary results were posted as of [search date].”
• “Summary results were posted for [each/the] primary outcome measure currently listed in the record; the record history [did/did not] support calling it prespecified before results were known.”
• “The record was last verified in [month year].”

Do not translate “registered,” “recruiting,” or “completed” into “proven,” “safe,” “effective,” or “FDA approved.” ClinicalTrials.gov expressly states that the U.S. government does not review or approve the safety and science of all listed studies; sponsors or investigators submit the information and are responsible for it.[6]

Part 2: Check FDA approval status

1. Search Drugs@FDA by multiple names

Search the compound’s exact name and documented synonyms in Drugs@FDA. FDA describes Drugs@FDA as containing information about most FDA-approved prescription, generic, over-the-counter, and many therapeutic biological products for human use, with daily updates.[7][8][14]

A credible match should lead to an application record. Verify:

• proprietary and established names;
• active ingredient or proper name;
• application number and applicant;
• approval letters and dates;
• current labeling;
• the specific approved indication and finished-product presentation.

A match for an ingredient does not mean every material bearing that ingredient name is approved. Approval belongs to the application and product described in the official record and labeling.

2. Check the Orange Book or Purple Book as appropriate

Use the Orange Book for FDA-approved drug products under new and abbreviated drug applications. It can be searched by active ingredient, proprietary name, applicant, or application number and includes product-specific fields.[9][10]

Use the Purple Book for FDA-licensed biological products. FDA’s Purple Book search identifies licensed products and their BLA numbers, including biosimilar and interchangeable products where applicable.[11]

These databases overlap with Drugs@FDA in useful ways, but they are not interchangeable. Document which database you searched and what field produced the match.

3. Do not treat identifiers or listings as approval

FDA’s Global Substance Registration System issues UNIIs based on substance identity characteristics and states that UNII availability does not imply regulatory review or approval.[12]

FDA also states that the National Drug Code Directory includes approved and unapproved listed products, that FDA does not necessarily verify submitted listing information, and that assignment of an NDC does not denote approval.[13]

Therefore, none of these alone proves approval:

• an NCT number;
• a recruiting or completed trial;
• a UNII;
• an NDC listing;
• a PubMed citation;
• a patent;
• a press release;
• use or authorization in another country.

4. Write an absence finding carefully

Database coverage and naming can complicate a negative search. Prefer:

No matching FDA-approved product was identified in Drugs@FDA, the Orange Book, or the Purple Book using the documented names searched on [search date].

Then list the search terms and databases. Do not turn a time-stamped search into an unqualified permanent claim. Recheck immediately before publication and on a defined maintenance schedule.

A reusable verification record

For every compound, preserve:

Important limitations

• ClinicalTrials.gov does not contain every study ever conducted, and record information is submitted by sponsors or investigators.[15]
• Registration, recruitment, completion, and posted results do not equal FDA approval.
• A database match must be verified against the exact application, product, labeling, and intended use.
• A no-match search can miss aliases, historical records, or products outside a database’s coverage.
• Regulatory status can change, so every status statement needs a reviewed-on date.
• FDA approval of a finished product does not transfer to a separately sourced research material with the same ingredient name.

Frequently asked questions

Does an NCT number mean FDA reviewed or approved the intervention?

No. It identifies a record in ClinicalTrials.gov. The site states that the U.S. government does not review or approve the safety and science of all listed studies.

Does “completed” mean a clinical trial was successful?

No. Completed means the study concluded normally and the last participant’s last visit occurred. It does not show success or that results were posted. If results are posted, evaluate every primary outcome, its time frame and analysis, and any prespecified success rule.

Does a Phase 3 listing prove approval is close?

No. A phase label describes a study stage. It does not reveal the result, guarantee an application, or predict an FDA decision.

Does a UNII mean a substance is FDA approved?

No. FDA states directly that UNII availability does not imply regulatory review or approval.

Does an NDC number mean a product is approved?

No. FDA states that the NDC Directory includes approved and unapproved products and that assignment of an NDC does not denote approval.

If an ingredient appears in an approved drug, is any version of that ingredient approved?

No. Approval is product- and application-specific. Verify the applicant, active ingredient or proper name, finished-product presentation, labeling, and approved indication.

What should I say when an FDA database search finds no match?

State that no matching approved product was identified in the named databases, using the listed search terms, on the stated date. Avoid an undated absolute claim.

How often should status be rechecked?

Recheck immediately before publication and whenever the page is materially updated. High-interest or active-development compounds warrant a shorter scheduled review interval than stable historical topics.

Primary and official sources

1. ClinicalTrials.gov: How to Read a Study Record
2. ClinicalTrials.gov Glossary
3. ClinicalTrials.gov: Protocol Registration Data Element Definitions
4. ClinicalTrials.gov: How to Read Study Results
5. ClinicalTrials.gov: Results Data Element Definitions
6. ClinicalTrials.gov Disclaimer
7. FDA: About Drugs@FDA
8. Drugs@FDA search
9. FDA: Orange Book Data Files and Field Definitions
10. FDA Orange Book search
11. FDA Purple Book search
12. FDA Global Substance Registration System / UNII Search
13. FDA National Drug Code Directory
14. FDA: Approved Drugs, Questions and Answers
15. ClinicalTrials.gov: About ClinicalTrials.gov

Review and corrections

Sources checked: September 1, 2026. Questions or corrections can be sent through the Serum Research contact page.

Editorial responsibility: Serum Research. This page was prepared from the primary and official sources listed above. No independent scientific, regulatory, or clinical review is claimed.

Research Library · How Serum Research reviews evidence · FDA-approved drug vs research material